Feedback
Navigate Up
  • Chat online
  • Write to us
  • 1800 22 1230

UTI - Pharma & Healthcare Fund

Rating (source: Value Research)

NAV as on 02/12/2016 for

Rs. 70.137-0.6504 (0.93%)
SMS: LNF to 5676756to get scheme details and NAV
  • Overview

  • Performance

  • Portfolio

  • Fund
    Manager
  • Scheme
    Documents
  • Load
    Structure
  • Management
    Commentary
  • Creation Unit/
    Portfolio
Investment Objective

Investment will be made in stocks of those companies engaged in the following areas:

  • The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.
Investment Information
Fund type
Open ended
Date of Inception
28/06/1999
Investment Plan
Dividend Option
Fund size (Rs.Cr)
333.89 (as of 31st Oct 2016 )
Number of investors
38770 (as of 31st Oct 2016 )
Min. Investment
5000
Last Dividend
1.7
Bonus
N.A.
Options Available

Growth option, Dividend option with Payout and Reinvestment

(SIP, SWP & Trigger)

Fund Managers
Fund Manager

Mr. Lalit Nambiar

Lalit Nambiar is a Commerce Graduate and has done his Masters of Management Studies (MMS) and Chartered Financial Analyst (CFA).

Know More
Who Should Invest
  1. Suitable for a regular equity investor who has a higher risk appetite. Such a fund can be used to complement their core portfolio holdings. Suggested investment horizon is 2- 3 years
Portfolio (as of Oct 2016)

Sectoral Breakdown
(% as compared to Benchmark)

Market Capitalisation (%)

Large Mid Small
73.00 24.00 3.00

View complete asset allocation

This product is suitable for investors who are seeking*:

  • Long term capital growth
  • Investment in equity instruments of companies in the Pharma & Healthcare sector
  • High Risk Level

* Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

Scenario 1:
Mr.Singh has invested Rs.1,00,000 in this fund since December 2000. See how his funds have performed over time.

Scenario 2:
Mr.Singh has invested Rs.1,00,000 in this fund since December 2000. See how his funds have performed over time.

Sectoral Breakdown (as of 31st Oct 2016)
Asset Allocation (as of 31st Oct 2016)

Market Capitalisation (%)

Large Mid Small
73.00 24.00 3.00
Detailed Portfolio (as of 31st Oct 2016)
Equity % to NAV
NCA 2.37
SANOFI INDIA LTD. 1.53
UNICHEM LABORATORIES 1.52
GLAXOSMITHKLINE PHARMACUETICALS LTD. 1.11
INDRAPRASTHA MEDICAL CORPORATION LTD. 1.10
NATCO PHARMA LTD. 1.06
DISHMAN PHARMACEUTICALS & CHEMICALS LTD. 0.88
TORRENT PHARMACEUTICALS LTD. 0.60
SHILPA MEDICARE LTD. 0.53
THYROCARE TECHNOLOGIES LTD. 0.14
PFIZER LIMITED 1.59
BIOCON LTD. 2.39
INDOCO REMEDIES LTD. 0.38
DIVIS LABORATORIES LTD. 4.97
STRIDES SHASUN LTD. 1.74
SYNGENE INTERNATIONAL LTD. 2.23
DR. REDDY'S LABORATORIES LTD. 11.75
CIPLA LTD. 9.34
AUROBINDO PHARMA LTD. 6.52
SUN PHARMACEUTICALS INDUSTRIES LTD. 21.50
PIRAMAL ENTERPRISES LTD. 3.94
ALKEM LABORATORIES LTD 3.60
CADILA HEALTHCARE LTD. 2.72
IPCA LABORATORIES LTD. 2.67
NARAYANA HRUDAYALAYA LTD 2.60
SUN PHARMA ADVANCED RESEARCH CO LTD. 2.56
LUPIN LTD. 8.66
Fund Manager - Biography
Fund Manager

Mr. Lalit Nambiar

Lalit Nambiar is a Commerce Graduate and has done his Masters of Management Studies (MMS) and Chartered Financial Analyst (CFA). He has been associated with UTI AMC Ltd. since December 2006. He is presently functioning as a Co-Fund Manager & Head of Research. He has an overall industry experience of 15 years having worked with good corporates like IIT Investrust Ltd., UTI Securities Exchange Ltd. and SBI Capital Markets Ltd.

Minimum Investment Amount Rs. 5000/-
Period of Holding

<= 548 days >548 days

Entry Load Nil
Exit Load(as % of NAV) Less than one year - 1%
Greater than or equal to one Year - Nil
Already have this Fund?

Things you should know to make the best investment decision

Register with us
and recieve benefits:

  • Get tips on investment
  • Bust your myths
  • Get NAV alerts
  • Recieve emails on market outlook
....and much more!

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

DESIGNED BY : Indigo Consulting
DEVELOPED BY :   Prosares Solution Pvt Ltd